Antifungal Drugs: Technologies and Global Markets

Published - Jun 2014| Analyst - Mary Anne Crandall| Code - PHM029E
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

The global market for human antifungal therapeutics reached nearly $11.6 billion in 2012 and $11.8 billion in 2013. This market is expected to grow to nearly $13.9 billion in 2018 with a compound annual growth rate (CAGR) of 3.2% over the five-year period from 2013 to 2018.

Report Includes

  • An overview of the global market for human antifungal therapeutics
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Identification of new antifungal research, development, and drug applications
  • Information on over the counter (OTC) vs. prescription products
  • Comprehensive profiles of leading companies in the industry.

SCOPE OF REPORT

This study examines human applications both currently marketed and in the development of antifungal technologies. In an extensive analysis, BCC Research examines each market segment, presents its current market status and offers various forecasts for growth over the next five years. Other factors such as Food and Drug Administration (FDA) restrictions, government legislation, fungal resistance and changes in consumerism such as a greater demand for OTC medications and/or natural and alternative remedies are also highlighted. Our financial and sales analysis focuses on the available figures from 2012 to 2013, with estimates for 2018, including CAGR as a percentage.

Analyst Credentials

Mary Anne Crandall is a medical research analyst and has specialized in the pharmaceuticals and medical device industry for the last 25 years. She has completed several in-depth studies on various medical topics requiring both expertise and knowledge of the industry. She is a retired nurse, has a B.S. and an M.S. in Psychology and is currently working on her Ph.D.

Select reports include:

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Jul-2012| Analyst - Mary Anne Crandall| Code - PHM029D

Report Highlights

The global market for antifungal therapeutics was valued at $10.7 billion in 2011 and is projected to reach $12.2 billion in 2016, a five-year compound annual growth rate (CAGR) of 2.7%.

Published - Apr-2010| Analyst - Michael Delander| Code - PHM029C

Report Highlights

  • The global market for human antifungal therapeutics was valued at $9.8 billion in 2009 and is expected to increase at a compound annual growth rate (CAGR) of approximately 3.8% to reach $11.3 billion in 2014.
  • The Latin and South American region will experience the greatest compound annual growth rate (CAGR) of 8.3%, reflecting an increase in revenues from $637 million in 2009 to $949 million in 2014.
  • In North America, human antifungal therapeutics were valued at $3.9 billion in 2009 and are expected to increase at a 0.7% compound annual growth rate (CAGR) to reach $4 billion in 2014.
Published - Mar-2007| Analyst - Danielle West| Code - PHM029B

Report Highlights

  • The total global market for antifungal agents was worth more than $13.5 billion in 2005 and declined to just under $12.2 billion in 2006. The market will continue to dip through 2007 to $11.9 billion but will recover to more than $14.7 billion, a compound annual growth rate (CAGR) of 2.8%
  • Antifungal agents for humans held the highest share of the market through the forecast period. In 2007 they will be worth more than $11.2 billion and will reach nearly $14 billion by 2012, a CAGR of 4.5%.
  • Trends for fungal infections among animals are still a major concern as industry trends indicate. The market for animal antifungals will be worth $107 million in 2007 and will reach $110.7 million by 2012, a CAGR of 3.5%.
Published - Apr-2003| Analyst - Lynn Gray| Code - PHM029A

Report Highlights

  • The market for antifungal drugs is estimated at $5.9 billion in 2002, including both prescription and OTC products.
  • Overall, the market is projected to rise at an average annual growth rate (AAGR) of 7.9% through 2007 to $8.7 billion.
  • There are about 30 branded prescription systemic and topical antifungal agents on the market and several dozen over-the-counter branded and generic topical antifungal products.
  • Products from several entirely new categories of compounds will be introduced during the forecast period.
  • More than a dozen new prescription products are in clinical development and will contribute to the growth in this market.

CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report